KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Biotechnology

Healthcare
$27.00 +0.00%

+$0.00 today

Market cap
$1.44B
Beta
-0.11
P/E (TTM)
-9.9
EPS (TTM)
-$2.74
52W Low $9.83High $27.00

Volume 4.26M

Average 3.47M

KALV Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

KalVista Pharmaceuticals, Inc.NASDAQ: KALV

Revenue · Q4 FY2026 · quarter ended Dec 2025

Revenue of $40.86M in Q4 FY2026

Q4 FY2026 revenue was $40.86M. Trailing-twelve-month revenue was $115.91M.

Context

  • Revenue increased in 1 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 3 analysts of $199.04M (+170.4%) for the fiscal year ending Dec 2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
$40.86M+198.4% QoQ
Last fiscal yearDec 2025
$73.62M— YoY
LTMDec 2025
$115.91M— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year—+170.4%—
3-year CAGR—+79.4%—
5-year CAGR+51.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2026
73.62M USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How KALV compares with its peers on the latest reported figures

  • KALV's LTM Dec 2025 revenue of $115.91M is the 2nd highest of the 10 companies compared; the peer median is $57.94M.
KALV Competitors Peer median
Revenue for KALV and competitors
Company Period LTM YoY 3-year CAGR
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$299.77M +47.6%+34.8%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$115.91M ——
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$88.24M +383560.9%+200.9%
ADCTADC Therapeutics S.A.LTM Mar 2026$79.18M +4.4%-27.1%
BCYCBicycle Therapeutics plcLTM Mar 2026$63.5M +146.9%+71.2%
PRTAProthena Corporation plcLTM Mar 2026$57.94M -58.0%-43.6%
GOSSGossamer Bio, Inc.LTM Mar 2026$55.54M -55.4%—
VSTMVerastem, Inc.LTM Mar 2026$49.59M +395.8%+128.4%
OMEROmeros CorporationLTM Mar 2026$9.89M ——
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$0 ——
Peer median (excluding KALV) $57.94M+47.6%+53.0%

Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Dec 2025
Revenue000073.62M
Cost of Revenue0086.17M06.08M
Gross Profit00(86.17M)067.54M
Gross Margin————91.7%
Research & Development70.17M80.28M86.17M71.71M55.64M
Selling, General & Admin26.45M30.6M54.28M116.29M183.74M
Operating Expenses96.61M110.87M54.28M188M239.38M
Depreciation & Amortization564K718K816K941K1.45M
EBITDA(80.75M)(94.37M)(134.28M)(173.33M)(150.62M)
EBITDA Margin————-204.6%
Operating Income(96.61M)(110.87M)(140.45M)(188M)(171.84M)
Operating Margin————-233.4%
Interest Income1.09M2.23M3.9M6.44M8.68M
Interest Expense0005.79M19.34M
Other Income / Expenses14.27M17.96M5.35M7.94M420K
Income Before Tax(82.34M)(92.91M)(135.1M)(180.05M)(171.42M)
Pre-Tax Margin————-232.9%
Income Tax Expense00(8.45M)3.39M(7.13M)
Net Income(82.34M)(92.91M)(126.64M)(183.44M)(164.29M)
Net Margin————-223.2%
EPS (Basic)(3.36)(3.33)(3.44)(3.69)(3.23)
EPS (Diluted)(3.36)(3.33)(3.44)(3.69)(3.23)
Weighted Avg Shares24.47M27.89M36.79M49.65M50.9M
Weighted Avg Shares (Diluted)24.47M27.89M36.79M49.65M50.9M

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Intrinsic Alpha fair value

Locked

Current Price

$27.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.